Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Financing Activities (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Cash from Financing Activities for 7 consecutive years, with $705.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 25405.21% to $705.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $990.7 million, a 62.72% increase, with the full-year FY2025 number at $990.7 million, up 62.72% from a year prior.
  • Cash from Financing Activities was $705.2 million for Q4 2025 at Kymera Therapeutics, up from $39.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $705.2 million in Q4 2025 to a low of -$206000.0 in Q3 2023.
  • A 5-year average of $100.4 million and a median of $1.9 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: plummeted 100.14% in 2023, then skyrocketed 121904.85% in 2024.
  • Kymera Therapeutics' Cash from Financing Activities stood at $2.1 million in 2021, then decreased by 4.92% to $2.0 million in 2022, then fell by 0.97% to $1.9 million in 2023, then soared by 42.97% to $2.8 million in 2024, then soared by 25405.21% to $705.2 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Cash from Financing Activities are $705.2 million (Q4 2025), $39.5 million (Q3 2025), and $245.7 million (Q2 2025).